Nghiên cứu đặc điểm lâm sàng, xét nghiệm và kết quả điều trị u lympho không hodgkin tế bào B lớn nguyên phát thần kinh trung ương tại Viện Huyết học Truyền máu Trung ương

To describe some clinical and laboratory characteristics of patients with primary central nervous system diffuse large Bcell lymphoma and evaluation of treatment results after 3 courses high dose methotrexate and rituximab. Subjects: 50 patients were treated at the National Institute of Hematology and Blood Transfusion from January 1st, 2020 to May 31st, 2022. Methods: descriptive crosssectional study, retrospection and prospection. Results: Focal neurologic deficit and headache were the most common symptoms (54% and 52%). Tumor lesions were seen in many locations, in which the frontal lobe accounted for the highest (30%). The percentage of patients positive with BCL2, BCL6, c-Myc by immunohistochemical staining was 84%, 86% and 30%, respectively. Non-germinal center B cell like subtype accounted for 94%. 39/50 patients were treated with enough courses of Methotrexate 8g/m2 combination with Rituximab and the percentage of patients with complete response was 56.4%. The overall response rate (CR+PR) of the BCL6-positive group was statistically significantly higher than that of the BCL6-negative group with p=0.01.